v3.19.3.a.u2
Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - AstraZeneca (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 22, 2016
Jan. 31, 2019
Sep. 29, 2019
Apr. 01, 2018
Jul. 02, 2017
Dec. 31, 2019
Dec. 31, 2017
Dec. 31, 2018
Business Acquisition [Line Items]                
Fair value of contingent consideration           $ 711,000,000   $ 988,000,000
Goodwill           58,653,000,000 $ 55,952,000,000 $ 53,411,000,000
AstraZeneca [Member]                
Business Acquisition [Line Items]                
Payments to acquire businesses, cash portion $ 555,000,000           $ 605,000,000  
Milestone payment       $ 125,000,000 $ 50,000,000      
Deferred payment   $ 175,000,000            
Potential milestone payments     $ 75,000,000          
Maximum amount of sales-related payments           600,000,000    
Consideration transferred 1,000,000,000.0              
Fair value of contingent consideration 485,000,000              
Intangible assets 894,000,000              
Other current assets 92,000,000              
Goodwill 73,000,000              
Net deferred tax liabilities 19,000,000              
Minimum [Member] | AstraZeneca [Member]                
Business Acquisition [Line Items]                
Royalty payments           315,000,000    
Maximum [Member] | AstraZeneca [Member]                
Business Acquisition [Line Items]                
Royalty payments           $ 542,000,000    
Developed Technology Rights [Member] | AstraZeneca [Member]                
Business Acquisition [Line Items]                
Intangible assets 728,000,000              
In Process Research and Development [Member] | AstraZeneca [Member]                
Business Acquisition [Line Items]                
Intangible assets $ 166,000,000